Comparative effectiveness and safety of bolus vs. continuous infusion of loop diuretics: Results from the MIMIC-III Database

被引:1
|
作者
Weng, Haoyu [1 ]
Li, Yuxi [1 ]
Nie, Xiaolu [2 ]
He, Chunhui [3 ]
Feng, Pengbin [4 ]
Zhao, Fengxin [4 ]
Chen, Qingjie [5 ]
Sun, Wen [6 ]
Jiang, Jie [1 ]
Zhang, Yan [1 ]
Huo, Yong [1 ]
Li, Jianping [1 ]
机构
[1] Peking Univ First Hosp, Dept Cardiol, Beijing, Peoples R China
[2] Beijing Childrens Hosp, Ctr Clin Epidemiol & Evidence Based Med, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Cardiol, Fuwai Hosp, Beijing, Peoples R China
[4] Beijing 1M data Tech Co Ltd, Beijing, Peoples R China
[5] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Xinjiang, Peoples R China
[6] Peking Univ First Hosp, Dept Respirat & Crit Care, Beijing, Peoples R China
来源
关键词
Loop diuretics; Continuous infusion; Bolus injection; Urine output; Acute kidney injury incidence; MIMIC-III data-base; DECOMPENSATED HEART-FAILURE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; STRATEGIES; PATIENT; KIDNEY; SAPS-3;
D O I
10.1016/j.amjms.2022.12.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is unclear whether fluid management goals are best achieved by bolus injection or continuous infusion of loop diuretics. In this study, we compared the effectiveness and safety of a continuous infusion with that of a bolus injection when an increased loop diuretic dosage is required in intensive care unit (ICU) patients.Methods: We obtained data from the MIMIC-III database for patients who were first-time ICU admissions and required an increased diuretic dosage. Patients were excluded if they had an estimated glomerular filtration rate <15 ml/min/1.73 m2, were receiving renal replacement therapy, had a baseline systolic blood pressure <80 mmHg, or required a furosemide dose <120 mg. The patients were divided into a continuous group and a bolus group. Propensity score matching was used to bal-ance patients' background characteristics.Results: The final dataset included 807 patients (continuous group, n = 409; bolus group, n = 398). After propensity score matching, there were 253 patients in the bolus group and 231 in the continuous group. The 24 h urine output per 40 mg of furosemide was significantly greater in the continuous group than in the bolus group (234.66 ml [95% confidence interval (CI) 152.13-317.18, p < 0.01]). There was no significant between-group difference in the incidence of acute kidney injury (odds ratio 0.96, 95% CI 0.66-1.41, p = 0.85).Conclusions: Our results indicate that a continuous infusion of loop diuretics may be more effective than a bolus injection and does not increase the risk of acute kidney injury in patients who need an increased diuretic dosage in the ICU.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 37 条
  • [11] Safety and Effectiveness of Prasugrel vs. Clopidogrel in the Setting of Bivalirudin vs. Heparin Use: 30-day Results from TRANSLATE-ACS
    Henry, Timothy D.
    Peterson, Eric
    Cohen, David
    Ju, Christine
    Stone, Gregg W.
    Messenger, John C.
    Fonarow, Gregg C.
    Effron, Mark B.
    Baker, Brian A.
    Zettler, Marjorie
    Wang, Tracy Y.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (11) : B145 - B146
  • [12] Comparative Effectiveness and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Evidence From Real World Practice
    Tsadok, Meytal Avgil
    Jackevicius, Cynthia A.
    Essebag, Vidal
    Eisenberg, Mark J.
    Rahme, Elham
    Humphries, Karin H.
    Tu, Jack V.
    Pilote, Louise
    CIRCULATION, 2013, 128 (22)
  • [13] Similar safety results of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) from a phase III trial in patients (pts) with previously untreated advanced gastric cancer (AGC)
    Kang, Y. K.
    Kang, W. K.
    Shin, D. B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M. P.
    Suarez, T.
    Santamaria, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 205 - 205
  • [14] Development and Comparative Analysis of an Early Prediction Model for Acute Kidney Injury within 72-Hours Post-ICU Admission Using Evidence from the MIMIC-III Database
    Luo, Yan
    Ye, Wenling
    Sun, Yawei
    Bao, Heling
    Liu, Hui
    DISCOVERY MEDICINE, 2023, 35 (177) : 623 - 631
  • [15] Database Linkage and Methodological Issues in Comparative Effectiveness Research (CER) of Medical Devices vs. Medications: Lessons from an Ongoing Project
    Jalbert, Jessica J.
    Chen, Chih-Ying
    Schneeweiss, Sebastian
    Hammill, Bradley G.
    Dreyer, Nancy A.
    Delaney, Joseph A. C.
    Gerhard, Tobias
    Setoguchi, Soko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S18 - S18
  • [16] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
    Kang, Y.
    Kang, W.
    Shin, D.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M.
    Suarez, T.
    Santamaria, J.
    ANNALS OF ONCOLOGY, 2006, 17 : 19 - 19
  • [17] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results.
    Kang, Y.
    Kang, W. K.
    Shin, D. B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M. P.
    Suarez, T.
    Santamaria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 183S - 183S
  • [18] Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 174 - 174
  • [19] Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, HJ
    Tabernero, J
    Nowacki, M
    Maroun, J
    Figer, A
    Price, T
    Lim, R
    van Cutsem, E
    Haller, D
    Braud, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [20] Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 26